CN113476425B - 一种pH响应性恩诺沙星纳米颗粒及其制备方法和应用 - Google Patents
一种pH响应性恩诺沙星纳米颗粒及其制备方法和应用 Download PDFInfo
- Publication number
- CN113476425B CN113476425B CN202110895811.2A CN202110895811A CN113476425B CN 113476425 B CN113476425 B CN 113476425B CN 202110895811 A CN202110895811 A CN 202110895811A CN 113476425 B CN113476425 B CN 113476425B
- Authority
- CN
- China
- Prior art keywords
- enrofloxacin
- responsive
- nps
- enr
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 title claims abstract description 79
- 229960000740 enrofloxacin Drugs 0.000 title claims abstract description 79
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 229920001661 Chitosan Polymers 0.000 claims abstract description 39
- 229940117916 cinnamic aldehyde Drugs 0.000 claims abstract description 31
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims abstract description 30
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims abstract description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 9
- 229940057995 liquid paraffin Drugs 0.000 claims description 9
- 239000003208 petroleum Substances 0.000 claims description 9
- 239000012154 double-distilled water Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 17
- 208000035143 Bacterial infection Diseases 0.000 abstract description 12
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 11
- 239000002253 acid Substances 0.000 abstract description 10
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- 238000005538 encapsulation Methods 0.000 abstract description 6
- 238000011068 loading method Methods 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 230000001960 triggered effect Effects 0.000 abstract description 4
- 239000006068 taste-masking agent Substances 0.000 abstract description 3
- 229930014626 natural product Natural products 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108020000946 Bacterial DNA Proteins 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010041052 DNA Topoisomerase IV Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种pH响应性恩诺沙星纳米颗粒及其制备方法和应用，该pH响应性恩诺沙星纳米颗粒由壳聚糖与肉桂醛接枝形成载体，封装恩诺沙星获得。本发明制得的pH响应性恩诺沙星纳米颗粒的平均药物包封率为76.6％，负载量为3.3％，具有单分散性、酸敏感性和酸触发药物释放特性，并且由于其优异的酸响应释放曲线和体外释放，使之可作为细菌感染DDS和苦味恩诺沙星的味道掩蔽剂。本发明使用的肉桂醛和壳聚糖是具有抗菌活性的天然产物，廉价且易于获得。
Description
技术领域
本发明属于抗菌药物技术领域，具体涉及一种pH响应性恩诺沙星纳米颗粒及其制备方法和应用。
背景技术
恩诺沙星属于氟喹诺酮类合成抗菌剂，是一种广泛采用的广谱抗生素，它对畜禽常见的呼吸道和肠道细菌性疾病和支原体有很好的防治作用。其抗菌机制是抑制细菌DNA促旋酶和拓扑异构酶IV，终止细菌DNA复制、转录、修复和细菌细胞壁的染色体分裂，从而阻断细菌DNA复制，达到抑菌目的。恩诺沙星的优点是抗菌杀菌作用迅速，口服吸收和组织分布极好，毒副作用小，血药浓度稳定，与其他抗生素无交叉耐药性，对治疗药用细菌感染引起的疾病具有抗药性。然而，恩诺沙星对胃肠道有很强的刺激性，在给药过程中容易引起动物应激，并且治疗过程中需要多次重复给药。普通恩诺沙星缓释制剂可以减少恩诺沙星的刺激性和给药次数，实现连续给药，但长期低剂量给药可能会增加药物副作用和耐药菌的风险。因此，开发有效的细菌反应性药物递送系统(BRDDS)是实现药物抑制细菌感染的必要条件。
在细菌感染过程中，细菌分泌多种活性因子，通过低氧发酵产生酸性物质降低周围pH值，最终形成独特的细菌感染微环境。而且，细菌感染部位具有类似于肿瘤组织的增强渗透和滞留(EPR)效应，有利于通过被动靶向转运向细菌感染部位聚集更多的纳米颗粒。当动物感染金黄色葡萄球菌等产酸菌后，细菌会在机体局部病灶处大量生长繁殖，病灶呈酸性状态。所以开发一种简单有效的策略来制备pH响应恩诺沙星递送系统和廉价的牲畜和家禽载体材料是非常必要的。
发明内容
本发明的目的是解决现有技术的不足，提供一种pH响应性恩诺沙星纳米颗粒及其制备方法和应用，具体采用以下的技术方案：
一种pH响应性恩诺沙星纳米颗粒，由壳聚糖与肉桂醛接枝形成载体，封装恩诺沙星获得。
优选地，所述pH响应性恩诺沙星纳米颗粒具有单分散性和酸敏感性。
优选地，所述pH响应性恩诺沙星纳米颗粒作为苦味恩诺沙星的味道掩蔽剂。
本发明还提供一种pH响应性恩诺沙星纳米颗粒的制备方法，包括如下步骤：
将肉桂醛逐滴加入含有壳聚糖的1％乙酸水溶液中，搅拌1h，得到第一混合物；将含有恩诺沙星的无水乙醇溶液逐滴加入SPAN80和液体石蜡的混合物中，得到第二混合物；将第一混合物缓慢加入至第二混合物中，并调节pH至6.3，40℃搅拌3-4h后，离心；残余物用石油醚和双蒸水反复洗涤，得到pH响应性恩诺沙星纳米颗粒(ENR-NPs)；
其中，肉桂醛：含有壳聚糖的1％乙酸溶液：含有恩诺沙星的无水乙醇溶液：SPAN80：液体石蜡＝1mL：20mL：2mL：2g：80mL；每20mL的含有壳聚糖的1％乙酸溶液中包括0.2g壳聚糖，每2mL的含有恩诺沙星的无水乙醇溶液中包括29.9-30.3mg恩诺沙星。
本发明采用壳聚糖与肉桂醛接枝形成载体，然后特定调节pH＝6.3并进行恩诺沙星的封装，从而制得了具有pH响应特性的恩诺沙星纳米颗粒。同时，带有肉桂醛的功能化壳聚糖产生了一种两亲性共聚物并充当了载体，在恩诺沙星的存在下形成了水包油(O/W)纳米乳液体系。当发生细菌感染，局部环境因细菌繁殖而酸化，从而会诱导具有pH响应特性的恩诺沙星纳米颗粒产生响应，导致恩诺沙星的释放。
优选地，所述采用10％NaOH调节pH至6.3。
优选地，离心条件为：12000rpm离心30min。
优选地，残余物用石油醚和双蒸水反复洗涤5次。
优选地，将pH响应性恩诺沙星纳米颗粒(ENR-NPs)冷冻干燥，储存在避光干燥处
本发明的有益效果为：本发明制得的pH响应性恩诺沙星纳米颗粒(ENR-NPs)的平均药物包封率为76.6％，负载量为3.3％，具有单分散性、酸敏感性和酸触发药物释放特性，并且由于其优异的酸响应释放曲线和体外释放，使之可作为细菌感染DDS和苦味恩诺沙星的味道掩蔽剂。本发明使用的肉桂醛和壳聚糖是具有抗菌活性的天然产物，廉价且易于获得。
附图说明
图1为本发明ENR-NPs的制备、pH触发释放机制及其抑菌效果图；
图2为本发明壳聚糖、CS-CA-NPs和ENR-NPs的X射线衍射图；
图3为本发明壳聚糖、肉桂醛、CS-CA-NPs和ENR-NPs的红外光谱；
图4为本发明ENR-NPs的透射电镜图像；
图5为本发明DLS分析的尺寸分布；
图6为本发明ENR-NPs的zeta电位；
图7为本发明pH＝5.0条件下释放12小时后的ENR-NPs透射电镜图像；
图8为本发明ENR-NPs在PBS溶液中的pH依赖性释放曲线；
图9为本发明恩诺沙星在pH值7.4或pH值5.0和ENR-NPs在pH值7.4或pH值5.0对金黄色葡萄球菌活性。
具体实施方式
以下将结合实施例和附图对本发明的构思及产生的技术效果进行清楚、完整的描述，以充分地理解本发明的目的、方案和效果。
本发明的材料和试剂：
壳聚糖(脱乙酰度≥95％，粘度100-200mpa.s)购自上海阿拉丁生化科技有限公司；
冰醋酸(纯度≥99.5％)、无水甲醇(纯度≥99.5％)、氢氧化钠(纯度≥99％)、二水磷酸二氢钠(纯度≥99％)、十二水磷酸氢二钠(纯度≥99％)、石油醚(60～90)、液体石蜡购自西陇科技有限公司；
肉桂醛(纯度≥95％)购自天津大茂化学试剂厂；
SPAN80购自国药集团化学试剂厂；
恩诺沙星(纯度≥98％)购自浙江国邦药业有限公司；
TSB培养基购自杭州基地生物科技有限公司；
金黄色葡萄球菌(ATCC25923)购自鲁威科技；
琼脂粉购自上海麦克林生化有限公司。
实施例1
制备pH响应性恩诺沙星纳米颗粒(ENR-NPs)
(1)将1mL肉桂醛逐滴加入20mL含有0.2g壳聚糖的1％(v/v)乙酸水溶液中，搅拌1h，得到含有肉桂醛和壳聚糖的混合物；
(2)将2mL含有30.1mg恩诺沙星的无水乙醇溶液逐滴加入2g SPAN80和80mL液体石蜡的混合物中，得到含有恩诺沙星的混合物；
(3)将含有肉桂醛和壳聚糖的混合物缓慢加入含有恩诺沙星的混合物中，并用10％NaOH调节溶液pH至6.3，40℃搅拌3.5h后，再以12000rpm离心30min，得到残余物；
(4)残余物用石油醚和双蒸水反复洗涤5次，得到pH响应性恩诺沙星纳米颗粒(ENR-NPs)；
(5)ENR-NPs沉淀冷冻干燥并储存在避光干燥处。
实施例2
制备pH响应性恩诺沙星纳米颗粒(ENR-NPs)
(1)将1mL肉桂醛逐滴加入20mL含有0.2g壳聚糖的1％(v/v)乙酸水溶液中，搅拌1h，得到含有肉桂醛和壳聚糖的混合物；
(2)将2mL含有29.9mg恩诺沙星的无水乙醇溶液逐滴加入2g SPAN80和80mL液体石蜡的混合物中，得到含有恩诺沙星的混合物；
(3)将含有肉桂醛和壳聚糖的混合物缓慢加入含有恩诺沙星的混合物中，并用10％NaOH调节溶液pH至6.3，40℃搅拌3.5h后，再以12000rpm离心30min，得到残余物；
(4)残余物用石油醚和双蒸水反复洗涤5次，得到pH响应性恩诺沙星纳米颗粒(ENR-NPs)；
(5)ENR-NPs沉淀冷冻干燥并储存在避光干燥处。
实施例3
制备pH响应性恩诺沙星纳米颗粒(ENR-NPs)
(1)将1mL肉桂醛逐滴加入20mL含有0.2g壳聚糖的1％(v/v)乙酸水溶液中，搅拌1h，得到含有肉桂醛和壳聚糖的混合物；
(2)将2mL含有30.3mg恩诺沙星的无水乙醇溶液逐滴加入2g SPAN80和80mL液体石蜡的混合物中，得到含有恩诺沙星的混合物；
(3)将含有肉桂醛和壳聚糖的混合物缓慢加入含有恩诺沙星的混合物中，并用10％NaOH调节溶液pH至6.3，40℃搅拌3.5h后，再以12000rpm离心30min，得到残余物；
(4)残余物用石油醚和双蒸水反复洗涤5次，得到pH响应性恩诺沙星纳米颗粒(ENR-NPs)；
(5)ENR-NPs沉淀冷冻干燥并储存在避光干燥处。
实施例4
制备壳聚糖-肉桂醛纳米颗粒(CS-CA-NPs)
(1)将1mL肉桂醛(CA)逐滴加入20mL含有0.2g壳聚糖(CS)的1％(v/v)乙酸水溶液中，搅拌1h，得到含有肉桂醛和壳聚糖的混合物；
(2)将2mL的无水乙醇溶液逐滴加入2g SPAN80和80mL液体石蜡的混合物中，得到混合物；
(3)将含有肉桂醛和壳聚糖的混合物缓慢加入步骤(2)制备的混合物中，并用10％NaOH调节溶液pH至6.3，40℃搅拌3.5h后，再以12000rpm离心30min，得到残余物；
(4)残余物用石油醚和双蒸水反复洗涤5次，得到壳聚糖-肉桂醛纳米颗粒(CS-CA-NPs)。
实施例5
CS、CS-CA-NPs和ENR-NPs的XRD分析
壳聚糖、CS-CA-NPs和ENR-NPs通过XRD显示的晶体结构，如图2所示。CS衍射图中在2θ＝12.05°和20.39°处的两个特征峰表明壳聚糖链的氢键和高度脱乙酰化的II型。当壳聚糖与肉桂醛偶联时，衍射峰在2θ＝12.05处消失，在2θ＝20.39处峰强度减弱，表明壳聚糖氨基与肉桂醛醛基之间的交联会破坏壳聚糖的晶体结构。恩诺沙星在ENR-NPs上的衍射峰表明恩诺沙星以固体形式分散在ENR-NPs中。
实施例6
壳聚糖、肉桂醛、CS-CA-NPs和ENR-NPs的FT-IR光谱分析
壳聚糖、肉桂醛、CS-CA-NPs和ENR-NPs使用傅里叶变换红外(FT-IR)光谱进行表征，如图3所示。CS-CA-NPs和ENR-NPs在1635cm-1处表现出亚胺中C＝N双键的特征峰。肉桂醛中HC＝O在1672cm-1处的特征峰明显减弱，表明肉桂醛的HC＝O与壳聚糖上的-NH2反应。
实施例7
载药量(LC)和包封率(EE)测定如下
EE(％)＝ENR-NPs中药物总量/添加药物总量×100
LC(％)＝ENR-NPs中药物总量/ENR-NPs总重量×100
分别取10mg实施例1-3制备的ENR-NPs分散在含有pH＝1.0的盐酸溶液的100mL容量瓶中，并搅拌24小时，12000rpm离心30min后，用紫外可见分光光度计在335nm处测量上清液的吸光度强度，计算实际恩诺沙星含量(ENR-NPs中的恩诺沙星浓度是根据吸光度强度与恩诺沙星浓度在pH＝1.0盐酸溶液中的线性关系计算得到的)。
载药量(LC)和包封率(EE)的测定结果如表1所示，可以看出，76.6％的平均恩诺沙星包封率和3.3％的平均载药量，表明其潜力应用。
表1ENR-NPs的载药量和包封率
实施例8
ENR-NPs的形态学
如图4所示，透射电子显微镜(TEM)记录ENR-NPs的形态特征。ENR-NPs的TEM图像显示出直径为120nm且单分散性良好的纳米颗粒的均匀实心球结构。
如图5所示，动态光散射(DLS)分析ENR-NPs的粒度分布，根据TEM显示的尺寸，可以看出，ENR-NP的平均直径为(135.00±16.94nm)。这可能是由于ENR-NPs在DLS液体样品制备过程中的膨胀效应而发生的。
如图6所示，ENR-NPs的zeta电位为3.52±4.65mV。
如图7所示，ENR-NPs在pH＝5.0、37℃条件下处理12小时后，由于其酸敏感电位，会发生腐蚀和聚集。
实施例9
ENR-NPs的体外释放研究
ENR-NPs在PBS溶液中的pH依赖性释放曲线如图8所示，可以看出，恩诺沙星在前120分钟内释放较快，给药后体内血药浓度可迅速达到治疗浓度。但120min后药物释放速率逐渐下降，并在接下来的10小时内继续缓慢释放。说明达到治疗浓度后，可以持续缓慢补充因代谢而损失的血药浓度，从而延长药物治疗时间，避免多次给药的最后期限。
对pH＝7.4、pH＝6.0和pH＝5.0下的ENR-NPs的药物释放速率的比较分析，可以看出，释放介质的酸度对恩诺沙星的释放速率有显着影响。在pH＝5.0的条件下，ENR-NPs的药物累积释放率达到88.12％，而在pH＝7.4时仅达到35.41％。该结果表明ENR-NPs处于中性环境时，不容易释放恩诺沙星，这大大减小了细菌产生耐药性的可能；同时，ENR-NPs能够在弱酸环境下即能实现恩诺沙星的快速释放，说明ENR-NPs具有很好的pH响应敏感性。
由于其纳米级结构和在身体pH水平下的低释放率，ENR-NPs用于治疗细菌感染的非口服给药很容易在组织中扩散和分布。随着细菌的繁殖和生长，感染区域的局部环境变得酸性。当ENR-NPs穿透感染区域时，ENR-NPs的球形结构被侵蚀，如图7所示，释放包被的恩诺沙星，从而达到靶向给药细菌的目的。相比之下，当ENR-NPs用作口服给药系统(DDS)时，由于口腔中性环境，恩诺沙星的释放率在5分钟内下降到2.58％，阻止了恩诺沙星对味蕾的刺激，同样，当进入胃的酸性(pH值范围1～3)环境时，药物迅速释放，达到及时治疗的目的。
上述结果表明，ENR-NPs可以达到pH触发药物递送的目的，用于非口服给药期间的按需细菌感染治疗或掩盖口服给药时恩诺沙星的强烈苦味。
实施例10
ENR-NPs的体外抗菌活性
平板孵育16小时后，ENR-NPs对金黄色葡萄球菌的体外抗菌活性，如图9所示。图中a为pH值7.4的恩诺沙星的抑菌圈；b为pH值为7.4的ENR-NPs的抑菌圈；c为pH值为5.0的恩诺沙星的抑菌圈；d为pH值为5.0的ENR-NPs的抑菌圈。a、b、c、d的金黄色葡萄球菌抑菌圈直径如表2所示。较大的抑菌圈(a)表明，恩诺沙星在pH＝7.4条件下对金黄色葡萄球菌的抗菌活性略强于pH＝5.0时的抑菌圈(c)。由于其在中性环境中的低释放率，与相同条件下的恩诺沙星的抑菌圈(a)相比，pH＝7.4时观察到的ENR-NPs的抑菌圈(b)小得多。然而，ENR-NPs在pH＝5.0时的抑菌圈(d)直径明显大于ENR-NPs在pH＝5.0时的抑菌圈(c)直径，表明酸性条件越强，ENR-NPs释放的药物就越多，证实了ENR-NPs的pH响应特性。
表2金黄色葡萄球菌抑菌圈直径
尽管本发明的描述已经相当详尽且特别对几个所述实施例进行了描述，但其并非旨在局限于任何这些细节或实施例或任何特殊实施例，而是应当将其视作是通过参考所附权利要求考虑到现有技术为这些权利要求提供广义的可能性解释，从而有效地涵盖本发明的预定范围。此外，上文以发明人可预见的实施例对本发明进行描述，其目的是为了提供有用的描述，而那些目前尚未预见的对本发明的非实质性改动仍可代表本发明的等效改动。
Claims (5)
1.一种pH响应性恩诺沙星纳米颗粒的制备方法，其特征在于，包括如下步骤：
将肉桂醛逐滴加入含有壳聚糖的1％乙酸水溶液中，搅拌1h，得到第一混合物；将含有恩诺沙星的无水乙醇溶液逐滴加入SPAN80和液体石蜡的混合物中，得到第二混合物；将第一混合物缓慢加入至第二混合物中，并调节pH至6.3，40℃搅拌3-4h后，离心；残余物用石油醚和双蒸水反复洗涤，得到pH响应性恩诺沙星纳米颗粒；
其中，肉桂醛：含有壳聚糖的1％乙酸溶液：含有恩诺沙星的无水乙醇溶液：SPAN80：液体石蜡＝1mL：20mL：2mL：2g：80mL；每20mL的含有壳聚糖的1％乙酸溶液中包括0.2g壳聚糖，每2mL的含有恩诺沙星的无水乙醇溶液中包括29.9-30.3mg恩诺沙星。
2.根据权利要求1所述的pH响应性恩诺沙星纳米颗粒的制备方法，其特征在于，采用10％NaOH调节pH至6.3。
3.根据权利要求1所述的pH响应性恩诺沙星纳米颗粒的制备方法，其特征在于，离心条件为：12000rpm离心30min。
4.根据权利要求1所述的pH响应性恩诺沙星纳米颗粒的制备方法，其特征在于，残余物用石油醚和双蒸水反复洗涤5次。
5.根据权利要求1所述的pH响应性恩诺沙星纳米颗粒的制备方法，其特征在于，pH响应性恩诺沙星纳米颗粒冷冻干燥，储存在避光干燥处。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110895811.2A CN113476425B (zh) | 2021-08-05 | 2021-08-05 | 一种pH响应性恩诺沙星纳米颗粒及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110895811.2A CN113476425B (zh) | 2021-08-05 | 2021-08-05 | 一种pH响应性恩诺沙星纳米颗粒及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113476425A CN113476425A (zh) | 2021-10-08 |
| CN113476425B true CN113476425B (zh) | 2022-08-05 |
Family
ID=77945825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110895811.2A Expired - Fee Related CN113476425B (zh) | 2021-08-05 | 2021-08-05 | 一种pH响应性恩诺沙星纳米颗粒及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113476425B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117771175B (zh) * | 2024-02-23 | 2024-06-07 | 中国农业科学院农业环境与可持续发展研究所 | 一种恩诺沙星纳米混悬剂及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104138356A (zh) * | 2013-05-09 | 2014-11-12 | 烟台职业学院 | 一种肉桂醛交联壳聚糖载药微球的制备方法 |
| WO2020149756A2 (en) * | 2019-01-19 | 2020-07-23 | Qatar Foundation For Education, Science And Community Development | Chitosan-based nanocomposite as an antimicrobial agent and corrosion inhibitor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108541866A (zh) * | 2018-04-26 | 2018-09-18 | 福州大学 | 一种肉桂醛-海藻酸钠-壳聚糖纳米粒及其制备方法 |
-
2021
- 2021-08-05 CN CN202110895811.2A patent/CN113476425B/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104138356A (zh) * | 2013-05-09 | 2014-11-12 | 烟台职业学院 | 一种肉桂醛交联壳聚糖载药微球的制备方法 |
| WO2020149756A2 (en) * | 2019-01-19 | 2020-07-23 | Qatar Foundation For Education, Science And Community Development | Chitosan-based nanocomposite as an antimicrobial agent and corrosion inhibitor |
Non-Patent Citations (3)
| Title |
|---|
| Facile one-pot synthesis of chitosan-based nanoparticles for pH-responsive enrofloxacin delivery;Jun-Lan Yang等;《Materials Today Communications》;20211010;第29卷;第102883页 * |
| 恩诺沙星胶束的制备及其酸控药物释放性能研究;杨俊岚等;《中国畜牧兽医学会兽医药理毒理学分会第十五次学术讨论会论文集》;20191013;摘要第3-9行 * |
| 杨俊岚等.恩诺沙星胶束的制备及其酸控药物释放性能研究.《中国畜牧兽医学会兽医药理毒理学分会第十五次学术讨论会论文集》.2019,1-8. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113476425A (zh) | 2021-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mallakpour et al. | Application of MOF materials as drug delivery systems for cancer therapy and dermal treatment | |
| Li et al. | The simultaneous loading of catechin and quercetin on chitosan-based nanoparticles as effective antioxidant and antibacterial agent | |
| Mohebali et al. | Layered biocompatible pH-responsive antibacterial composite film based on HNT/PLGA/chitosan for controlled release of minocycline as burn wound dressing | |
| Portero et al. | Reacetylated chitosan microspheres for controlled delivery of anti-microbial agents to the gastric mucosa | |
| Gupta et al. | Synthesis of chitosan-g-poly (acrylamide)/ZnS nanocomposite for controlled drug delivery and antimicrobial activity | |
| Tzankov et al. | Development of MCM-41 mesoporous silica nanoparticles as a platform for pramipexole delivery | |
| CN112546027B (zh) | 载脂溶性色素纳米粒及其制备方法 | |
| Reddy et al. | Dual responsive pectin hydrogels and their silver nanocomposites: swelling studies, controlled drug delivery and antimicrobial applications | |
| CN113476425B (zh) | 一种pH响应性恩诺沙星纳米颗粒及其制备方法和应用 | |
| El-Batal et al. | Fabrication and characterization of cobalt hyaluronic acid nanostructure via gamma irradiation for improving biomedical applications | |
| Pletzer et al. | Rapid microwave-based method for the preparation of antimicrobial lignin-capped silver nanoparticles active against multidrug-resistant bacteria | |
| Pooresmaeil et al. | Chitosan based nanocomposites for drug delivery application | |
| Yıldırım et al. | Development of doxycycline and atorvastatin-loaded chitosan nanoparticles for local delivery in periodontal disease | |
| Aliahmadi et al. | Preparation nanocapsules chitosan modified with selenium extracted from the Lactobacillus acidophilus and their anticancer properties | |
| Kishore et al. | The multifaceted role of pectin in keratin based nanocomposite with antimicrobial and anti-oxidant activity | |
| Tong et al. | Preparation and characterization of berberine hydrochloride and trimethoprim chitosan/SBE7-β-CD microspheres | |
| Ashvini et al. | Clarithromycin-loaded Chitosan Nanoparticles: Preparation, Characterisation and Antibacterial Activity on Streptococcus pneumonia. | |
| Shikuku et al. | Chitosan-based pH-sensitive semi-interpenetrating network nanoparticles as a sustained release matrix for anticancer drug delivery | |
| Semwal et al. | Chitosan: a promising substrate for pharmaceuticals | |
| EP3240527B1 (en) | Essential oil loaded mucoadhesive nanocomposite delivery system for gastrointestinal system | |
| TWI690330B (zh) | 藥物載體、藥物結構、其用途、其製備方法及使用其抑制幽門桿菌之方法 | |
| US11318090B1 (en) | In situ gelling composition as a pH-selective and mucoadhesive sustained release drug delivery system | |
| Yang et al. | Facile one-pot synthesis of chitosan-based nanoparticles for pH-responsive enrofloxacin delivery | |
| Avhad et al. | Formulation and evaluation of chitosan based polyelectrolyte complex of levodopa for nasal drug delivery | |
| Arianto et al. | Floating gastroretentive of amoxicillin using hard alginate capsules and its antibacterial activities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220805 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |